These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2939597)

  • 1. Prevention of GvHD by a lymphokine.
    van Bekkum DW; Knaan-Shanzer S
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):159-64. PubMed ID: 2939597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble factors secreted by naturally occurring suppressor cells that interfere with in vivo graft-vs.-host disease and with T cell responsiveness in vitro.
    Knaan-Shanzer S; Van Bekkum DW
    Eur J Immunol; 1987 Jun; 17(6):827-34. PubMed ID: 2954829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural suppressor (NS) activity from murine neonatal spleen is responsive to IFN-gamma.
    Maier T; Holda JH
    J Immunol; 1987 Jun; 138(12):4075-84. PubMed ID: 2953798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective growth of murine newborn-derived suppressor cells and their probable mode of action.
    Jadus MR; Parkman R
    J Immunol; 1986 Feb; 136(3):783-92. PubMed ID: 2934478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease.
    Leibnitz RR; Lipsky PE; Thiele DL
    J Immunol; 1994 Dec; 153(11):4959-68. PubMed ID: 7963559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of cell-mediated immune responses after total lymphoid irradiation (TLI). I. Characterization of suppressor cells of the mixed lymphocyte reaction.
    Weigensberg M; Morecki S; Weiss L; Fuks Z; Slavin S
    J Immunol; 1984 Feb; 132(2):971-8. PubMed ID: 6140288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
    J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells.
    Thiele DL; Charley MR; Calomeni JA; Lipsky PE
    J Immunol; 1987 Jan; 138(1):51-7. PubMed ID: 2946780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous IFN-beta production. A common feature of natural suppressor systems.
    Cleveland MG; Lane RG; Klimpel GR
    J Immunol; 1988 Sep; 141(6):2043-9. PubMed ID: 2971719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-induced cytotoxic cell generation in thymus and spleen cell cultures.
    Biasi G; Rivarollo R; Colmagro R; Ronchese F; Collavo D
    J Biol Regul Homeost Agents; 1987; 1(3):119-25. PubMed ID: 3509738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine IL-10 fails to reduce GVHD despite inhibition of alloreactivity in vitro.
    Emmanouilides CE; Luo J; Baldwin G; Buckley D; Lau P; Lopez E; Tabibzadeh S; Yu J; Wolin M; Rigor R; Territo M; Black AC
    Bone Marrow Transplant; 1996 Aug; 18(2):369-75. PubMed ID: 8864448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of cytotoxic T lymphocytes requires at least two spleen cell-derived helper factors besides interleukin 2.
    Falk W; Männel DN; Dröge W
    J Immunol; 1983 May; 130(5):2214-8. PubMed ID: 6220085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory effect of cyclophosphamide-induced MAC-1+ natural suppressor cells on IL-2 and IL-4 utilization in MLR.
    Brooks JC; Hoskin DW
    Transplantation; 1994 Nov; 58(10):1096-103. PubMed ID: 7974716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirement for three distinct lymphokines for the induction of cytotoxic T lymphocytes from thymocytes.
    Takai Y; Herrmann SH; Greenstein JL; Spitalny GL; Burakoff SJ
    J Immunol; 1986 Dec; 137(11):3494-500. PubMed ID: 3097123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.